

AD _____

GRANT NUMBER: DAMD17-96-1-6133

TITLE: ERBB-Receptors and Drug Response in Breast Cancer

PRINCIPAL INVESTIGATOR: Lindsay Harris, M.D.

RECIPIENT ORGANIZATION: Georgetown University
Washington, DC 20057

REPORT DATE: September 1999

TYPE OF REPORT: Annual Report

PREPARED FOR: Commander
U.S. Army Medical Research and Materiel Command
504 Scott Street
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;
distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20010122 077

REPORT DOCUMENTATION PAGE			Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.				
1. AGENCY USE ONLY (Leave Blank)	2. REPORT DATE September 1999	3. REPORT TYPE AND DATES COVERED Annual (15 Aug 98 - 14 Aug 99)		
4. TITLE AND SUBTITLE ERBB-Receptors and Drug Response in Breast Cancer		5. FUNDING NUMBERS DAMD17-96-1-6133		
6. AUTHORS Lyndsay Harris, M.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Georgetown University Washington, DC 20057		8. PERFORMING ORGANIZATION REPORT NUMBER		
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command MCMR-RMI-S 504 Scott Street Fort Detrick, Maryland 21702-5012		10. SPONSORING / MONITORING AGENCY REPORT NUMBER		
11. SUPPLEMENTARY NOTES This report contains colored photos				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution unlimited		12b. DISTRIBUTION CODE		
13. ABSTRACT (Maximum 200 words) There is a compelling need for better ways to select cytotoxic therapy for a given patient with breast cancer. The role of the members of the type 1 growth factor receptor family (erbB1-4) and their ligands in predicting response to chemotherapy is still unknown. Clinical data support the role of the erbB2 receptor in resistance to some chemotherapeutic agents, mainly alkylators, while a dose-response effect to a doxorubicin-containing regimen has been seen. One potential explanation for this finding is our observation of upregulation of topoisomerase II (topo II) and sensitivity to doxorubicin, in cells in which the erbB2 and erbB3 and erbB4 receptors have been activated by the growth factor heregulin. Using EGFR-erbB chimera cells activated by EGF, we will determine which receptor is responsible for the phenotype of change in topo II levels and drug sensitivity. In addition, breast cancer cell lines with known expression of erbB receptors will be stimulated with EGF, amphiregulin and heregulin growth factors and topoisomerase changes will be measured. We also propose to examine the expression and activity of the topo II enzyme after erbB2 overexpressing cells are exposed to anti-erbB2 antibodies, many of which cause receptor phosphorylation. This allows us to explore the mechanism of topo II upregulation in cells with activated erbB receptors using a product with potential therapeutic efficacy. We will attempt to elucidate the mechanism of changes in topo II with erbB signalling by examining levels of DNA repair enzymes, changes in cell cycle and topo II promoter regulation. These studies will allow selection of erbB2 positive patients appropriate therapy to improve outcome and minimize toxicity.				
14. SUBJECT TERMS erbB receptors, II, doxorubicin, ligands, anti-erbB2 antibodies, DNA repair enzymes topoisomerase breast cancer			15. NUMBER OF PAGES 15	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

Where copyrighted material is quoted, permission has been obtained to use such material.

Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

Citations of commercial organizations and trade names in this report do not constitute an official Department of the Army endorsement or approval of the products or services of these organizations.

In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

In conducting research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

TABLE OF CONTENTS

FRONT COVER:	1
SF298:	2
FOREWORD	3
TABLE OF CONTENTS:	4
INTRODUCTION:	5-6
BODY:	6-11
REFERENCES:	11
APPENDICES: (Figures)	12-15

1999 Annual Report for Grant Number DAMD17-96-1-6133

Introduction

There is a compelling need for better ways to select cytotoxic therapy for a given patient with breast cancer. The members of the type 1 growth factor receptor family (*ErbB1-4*) appear to have a role in predicting benefit from chemotherapy, particularly *ErbB2*. The mechanisms by which these growth factors alter cellular pathways to change drug response is poorly understood, however. The objective of this proposal is to identify how this family of growth factors, particularly *ErbB2*, can be used to predict and control drug sensitivity in patients with breast cancer.

While it is well established that growth factors and their receptors play a role in the prognosis of breast cancer, recent data suggest they may have a role in predicting response to therapy as well. In general, the EGFR (Epidermal Growth Factor Receptor) and *ErbB2* receptors are associated with resistance to some chemotherapeutic agents, especially alkylator-based regimens such as cyclophosphamide, methotrexate and 5-fluorouracil (CMF). Interestingly, benefit from a doxorubicin (Adriamycin®)-containing regimen was limited to *ErbB2* overexpressors in three large randomized cohorts of patients, the CALGB 8869/8541, SWOG and NSABP-B14 companion studies. One potential explanation for this finding is our observation of up regulation of the DNA modifying enzyme and target of doxorubicin, topoisomerase II (topo II), in cells in which the *ErbB2*, *ErbB3* and *ErbB4* receptors have been activated using the ligand, heregulin¹. These cells become more sensitive to doxorubicin and etoposide, both topo II inhibitors. We hypothesize that signaling through one or a combination of the *ErbB* receptors in breast cancer cells increases topoisomerase II which then sensitizes cells to doxorubicin. This predicts that alteration of *ErbB* signaling by various agents (natural or synthetic) may control response to doxorubicin in a predictable fashion *in vitro* and *in vivo*. In this proposal, we are examining the relationship between activation of the *ErbB* receptors using various ligands (EGF, Heregulin and anti-receptor antibodies) and topoisomerase II regulation.

We propose that the biology of the change in topo II activity may be understood by global changes in DNA repair enzymes, brought about by signaling through the EGFR superfamily. During the time of this award we have shown that *ErbB2* signaling has an effect on cell cycle distribution of the topo II enzyme and its phosphorylation state, leading to increased sensitivity to doxorubicin but resistance to the alkylator cyclophosphamide². We have also made the novel discovery that topo II is phosphorylated on tyrosine residues as opposed to serine/threonine as previously described³. This effect is seen in response to *ErbB2*-mediated signaling, but not *ErbB3*, and we believe that this phosphorylation event may be important to determining sensitivity to doxorubicin.

This information will allow the use of biological agents with cytotoxic therapy in combination to produce highest tumor response rates. It will also allow selection of appropriate patients (ie those which over express *ErbB2* or other members of the *ErbB* family, or possibly topo II itself) for a given biological therapy directed at a specific molecular target. Patients whose tumors overexpress a given *ErbB* receptor, particularly if the receptor can be shown to be activated, may benefit from doxorubicin-containing

regimens. By investigating the role of type I growth factors in predicting response to therapy we draw closer to better selecting patients who will benefit from our treatments and avoiding toxicity in those who do not.

Technical objectives (specific aims as listed in 1996 proposal)

Aim1: To determine if one of the *ErbB2/3/4* receptors is responsible for the increased topoisomerase II and change in drug sensitivity seen when heregulin is transfected into cancer cells we propose to examine these endpoints in cell lines in which the individual receptors are activated.

Aim 2: To demonstrate whether specific ligands (antibodies, growth factors or compounds which modulate tyrosine kinase phosphorylation) can predictably alter sensitivity of breast cancer cells to doxorubicin and alkylators by topoisomerase II modulation mediated through *ErbB* receptor phosphorylation.

Aim 3: To determine the mechanism of topoisomerase II accumulation in *ErbB* receptor-activated cells we will examine three alternative explanations:

3a) Topoisomerase II upregulation is part of a global effect on DNA repair machinery

3b) Distribution of cell cycle in breast cancer cells is altered by activation of the *ErbB2* receptor to produce an accumulation of topoisomerase II .

3c) Accumulation of topoisomerase II in breast cancer cells with activation of the *ErbB* receptors is due to increase activity of the topo II promotor directly.

Results

During the first two years of the proposal we determined that *ErbB2* signaling led to increased topoisomerase II levels. We also made the novel discovery that signaling through this receptor leads to hyperphosphorylation of topo II which appeared to be on tyrosine residues. This discovery is unique as it has heretofore been thought that topo II activity is regulated by serine/threonine phosphorylation of the protein. We further characterized this relationship by evaluating both the cell cycle distribution of topo II levels and phosphorylation in *ErbB* positive vs negative cells lines (see 1998 annual report). We also evaluated the effect of these changes in topo II on its enzymatic activity in response to signaling by *ErbB* receptors. We found that topo II was upregulated and its ability to cleave DNA was increased in response to *ErbB* signaling. In addition, topo II was a more sensitive target for doxorubicin and etoposide in cells with *ErbB2* activation but not with *ErbB3* alone. Alkylator (cyclophosphamide) resistance seemed to be common to activation of either receptor, however. We postulated that the tyrosine phosphorylation of topo II (seen only upon *ErbB2* activation) was responsible for the doxorubicin sensitivity whereas alkylator resistance might be caused by changes in topo II levels alone.

Tyrosine Phosphorylation on Topo II α

During this third year we have focused our efforts on attempted characterizing tyrosine phosphorylation on Topo II α following ErbB2 signaling. We did this by using PTP-1B, (Protein Tyrosine Phosphatase 1B, Upstate Biotechnology) a tyrosine phosphatase, looking for a band shift in topo II α which would be supportive evidence of tyrosine phosphorylation of topo II α . These experiments did not yield evidence of a band shift, although tyrosine-specific antibodies did reveal a specific band at the appropriate size for topo II α (see Fig. 1).

Explanations for this finding are: 1)lack of tyrosine phosphorylation on topo II α ; 2) Lack of mobility shift in topo II α upon dephosphorylation 3) Endogenous phosphatases present which had dephosphorylated topo II α during the nuclear extraction procedure, therefore no change in phosphorylation would be seen upon phosphatase treatment.

We attempted to identify a candidate nuclear tyrosine kinase which might be responsible for phosphorylation of topo II α . Using a kinase assay with c-abl as the kinase (R. Quackenbush) and purified N-terminal topo II α as the substrate (provided by Dr. Tao Hsieh), we did not see specific phosphorylation of topo II α .

ErbB2-Inducible System

We attempted to create an inducible system for ErbB2 using the Tet-off® system (see Fig 2). We were able to create stable transfectants in MCF-7 cells with the pTet-off regulator plasmid and demonstrate, using a lac-z that the system could be induced. However, after co-transfection with pBI-SUPER-erbB2 and selection of dozens of clones, we were unable to demonstrate clones which were inducible for ErbB2 protein. We concluded that our difficulty was peculiar to our construct.

METHODS

Nuclear Protein Extraction for Phosphatase Assay

Ref. The Journal of Biological Chemistry vol. 272, No. 2, 91283-91290

1. Wash cells twice in ice-cold PBS, scrape the cells with a rubber policeman, and collect the cells. Centrifuge for 10 min. at 2000 rpm at 4 deg. C. (Note: Cells should be kept on ice.)
2. Quickly wash the cells in buffer A.

Buffer A	Stock	For 25ml
10mM Hepes pH 7.4	.5M pH 7.6	.5ml
1.5mM MgCl ₂	2M	18.75ul
10mM KCl	1.2M	208.5ul
0.5mM DTT	1M	12.5ul
50uM PMSF	100mM	12.5ul

dH2O 24.2ml

3. Spin at 2000 rpm at 4 deg. C for 10 min.
4. Suspend pellet in buffer A + 0.1% Nonidet P-40. Incubate on ice for 10 min. or more until no cytoplasm is present upon examination under microscope.
5. Collect nuclei by spinning at 2000 rpm at 4 deg. C for 10 min. Then suspend the nuclei in 500ul Buffer B.

Buffer B	Stock	For 10ml
20mM Hepes pH 7.4	.5M pH 7.6	400ul
1.5mM MgCl ₂	2M	7.5ul
420mM NaCl	5M	840ul
1mM DTT	1M	10ul
50uM PMSF	100mM	5ul
.2mM EDTA	.5M	4ul
25% Glycerol	100%	2.5ml
dH2O		6.23ml

6. Incubate on ice for 30 min.
7. Ultraspinn at max. speed for 15 min. at 4 deg.
8. Collect supernatant and quantitate protein.

Immunoprecipitation of Nuclear Extract with Topo II ab

1. Thaw nuclear protein on ice. Use PBS + phosphatase and protease inhibitors to bring volume up to 500ul.

PBS + Inhibitors	Stock []	Final []
10ml PBS		
100ul PMSF	100mM (in ethanol)	1mM
10ul Leupeptin	1mg/ml	1ug/ml
10ul Aprotinin	1mg/ml	1ug/ml
10ul Pepstatin	1mg/ml (in methanol)	1ug/ml
50ul Na ₃ VO ₄	200mM	1mM
50ul NaF	200mM	1mM

2. Add 40ul of protein A agarose beads and rock for 1 hr. at 4 deg. C.
3. Centrifuge for 15 min. at 4 deg. C at 15,000 rpm.
4. Collect sup., add PBS + inhibitors up to 1ml so protein conc. is approx. 0.5-1.0ug/ul. Add Topo II ab (~20ul) [Topogene] or rabbit IgG (~2.5ul of 3mg/ml stock).
5. Rock O/N at 4 deg. C.
6. Add 100 uL of protein agarose beads. Rock for 2 hrs. at 4 deg. C.
7. Spin for 5 min. at 4 deg. C at 15,000 rpm.
8. Discard sup. and wash beads 3X in cold modified RIPA buffer.
9. Resuspend beads in 80ul of 2X sample buffer [ISS] and heat for 5 min. at 100 deg. C, vortexing 2X during heating.
10. Microcentrifuge for 5 min. and load sup. on gel.

Digestion of Phosphoproteins with Protein Tyrosine Phosphatases.

Sample containing 10 to 100 µg total protein
 50 mM imidazole, pH 7.5
 Protein tyrosine phosphatase (e.g., PTP-1B or SH-PTP)
 2x SDS-PAGE sample buffer (see Basic Protocol 1) *or* 100 mM sodium vanadate

1. Incubate the sample (containing 10 to 100 µg total protein) in 50 mM imidazole, pH 7.5, for 10 min at 37°C.
2. Add 1 to 5 U protein tyrosine phosphatase and incubate 15 to 30 min at 37°C.

One unit of phosphatase activity hydrolyzes 1 nmol p-nitrophenyl phosphate (PNPP) in 1 min at 37°C and pH 7.0.

3. Terminate the dephosphorylation reaction by adding an equal volume of 2x SDS-PAGE sample buffer *or* 100mM sodium vanadate to a final concentration of 0.1 mM.
4. Analyze digested material by gel electrophoresis and immunoblotting.

Kinase Assays

Radioactive kinase assays were carried out in 40 μ l kinase assay buffer (50 mM Tris, pH 7.4, 10 mM MgCl₂) containing 10 μ Ci [γ -³²P]ATP for 15 min at 30°C. Reactions were terminated by addition of an equal volume of SDS sample buffer, boiled and analyzed by SDS-PAGE. Sf9 cells that had been co-infected with viruses encoding CDC2K33 and cyclin B were lysed by brief sonication in kinase assay buffer containing okadaic acid, sodium vanadate and protease inhibitors, the lysate being clarified by centrifugation at 70000 g for 20 min. Aliquots of the supernatant (20 μ l, 15 mg/ml) were supplemented by addition of an ATP regenerating system and mixed with an equal volume of He La cells lysate (20 mg/ml) or with anti-c-Abl immune precipitates (derived from 100 μ l 20 mg/ml HeLa cell lysate). Reactions were incubated at 30°C for 15 min and terminated by addition of SDS. The products were run on 12% Laemmli gels and analyzed by anti-phosphotyrosine blotting using antibody from UBI and the ECL detection system (Amersham). The final concentrations of the ATP regenerating system were 2 mM ATP, 20 mM creatine phosphate, 100 μ l/ml creatine phosphate kinase.

Creation of Tet-off® Transfectants (see Figure 2)

Summary

This year has not been as productive for several reasons. First, a number of different experimental approaches used to further characterize tyrosine phosphorylation on topo II either gave negative results or we were not able to get the technique working. We were unable to create stable transfectants of inducible ErbB2 in the Tet-off system. Finally, a move of the laboratory to the Dana-Farber from Duke University led to a temporary interruption of experimental work.

My laboratory is still very devoted to this work and will continue to investigate the ErbB2-topo II connection in the following ways:

Future Directions

- 1 In our further experiments we plan to do phosphoaminoacid analysis of topo II α by performing immunoprecipitation of topo followed by digestion with residue-specific proteases. We will then analyze by gel electrophoresis and detect with our tyrosine specific antibodies. We will perform 2-D gel electrophoresis if there is any ambiguity as to the source of the phosphorylated residues. We anticipate the phosphorylated tyrosines will be in the N-terminal fragment, where the candidate residues for tyrosine phosphorylation lie based on 3-D structural analysis (see Fig 3).
2. Given our lack of success with the tet-off® inducible system at creating an ErbB2 inducible cell line we will attempt infection with a recombinant adenovirus

containing erbB2 (in collaboration with Dr. Alex Miron, PhD) and look at short-term transfection of ErbB2 for changes in topo II and drug sensitivity in breast cancer cells which do not express ErbB2 endogenously.

3. We believe that the increase in topo II activity seen after ErbB2 signaling is part of a global effect on DNA repair activity. Using pulse-field electrophoresis (in collaboration with Dr. David Livingston's lab) and the excision/repair plasmid assay we will evaluate the DNA damage/repair response in cell lines after ErbB2 activation.
4. Using Northern blotting and CAT assays we will evaluate transcriptional activity of topo II α after ErbB2 activation in both chimeric receptor cells and breast cancer cells which overexpress ErbB2.

Harris L, Tang C, Yang C, Harris A, Lupu R. Induction of Chemotherapy Sensitivity in MCF-7 Breast Cancer Cells by Heregulin. *Clinical Cancer Research* 4: 1005-1012, 1998.

Yang L, Liocheva V, Colvin OM, Harris LN. Different Response to Adriamycin vs Cytosine-based chemotherapy in ErbB2 positive breast cancer is associated with alteration in topoisomerase II expression. 21st Annual San Antonio Breast Cancer Symposium, Dec. 1998.

Yang L, Liocheva V, Colvin OM, Harris LN. Signaling Through the ErbB2 Receptor Leads to Alteration in Topoisomerase II and Changes in Chemotherapy Response in Breast Cancer Cells. #2156 Proceedings of American Association for Cancer Research, New Orleans, LA, 1998.

APPENDIX

FIGURES




Figure 1


a) Creation of MCF-7/*erbB2*-Tet-off® Transfectants:


ErbB2 inducible cells were cotransfection with the plasmid pBI-SUPER-*erbB2* and pTK-Hyg into MCF-7 cells which have previously been transfected with pTet-off regulator plasmid as detailed in the manufacturer's instructions for the Tet-off® Gene Expression System, Clontech, CA (see figure 4). The cells will be grown in the presence of hygromycin selection medium and stable clones will be isolated.

Each clonal cell line was tested for induction of *erbB2* gene activity by removing tetracycline from the media and evaluating expression of *erbB2* message or protein level/activity. Expression of *erbB2* message was assessed using Northern blot probing:

Twenty micrograms of mRNA will be run on 1% agarose/formaldehyde gel by electrophoresis. Intact 18S and 28S bands seen by ethidium bromide staining are used to verify integrity of mRNA and the gel will be subject to Northern blot analysis¹. After extensive washes under standard conditions bands will be visualized by autoradiography. Loading and transfer efficiency will be normalized with a housekeeping gene, GAPDH, under the same conditions.

Protein expression was assessed using antibody 3B5 (Calbiochem, MA) under conditions optimized for Western blotting. Whole cell extracts will prepared from MCF7 transfectants and protein separated using 4-20% SDS-PAGE, transferred onto nitrocellulose and incubated with a mouse monoclonal Antibodies (Ab) against either *ErbB2* intracellular domain (Calbiochem, San Diego, CA) or antiphosphotyrosine antibody 4G10 (Upstate Biotechnology, New York) to assess tyrosine kinase activity of the *erbB2* receptor. Cells with high number of receptors per cell (equal or greater expression than SKBR3 breast cancer cells which have *erbB2* amplification) or high levels of tyrosine phosphorylation of *erbB2* on Western blot will be selected for further experiments. Cells will be maintained in tetracycline containing medium to suppress *erbB2* gene expression prior to experiments.





Prokaryotic DNA Gyrase
Eukaryotic DNA TOPO II α